Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease.
Enrolling By Invitation
18 years - 99 years
All
Phase
3
12 participants needed
1 Location
Brief description of study
This is a Phase 3, prospective, open-label, international, multicentre study of Flurpiridaz (18F) Injection
for PET MPI in patients referred for ICA because of suspected CAD. Five hundred and fifty-two (552)
evaluable subjects will be enrolled in this study, and will undergo SPECT MPI and Flurpiridaz (18F)
Injection PET MPI, prior to ICA.
Patients can be considered for enrolment if:
- They are being scheduled via written documentation at the time of enrolment to undergo ICA, and
- They have undergone a clinically indicated SPECT study which meets all study-specified imaging
and stress testing criteria, or are willing to undergo SPECT MPI for the purposes of the
clinical study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Coronary Artery Disease
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 832345
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
